| Dosing and Adminstration | Pricing and Access | Clinical Trials | Warnings and Precautions and Adverse Events |
|---|---|---|---|
|
What are 2000, 3000, 4,000, 10,000 and 40,000
Retacrit is available in single dose vials SC and IV administration in the following units
|
What is Pfizer Oncology Together
For comprehensive reimbursement and patient support services intended to help patients navigate their reimbursement process for Nyvestym and Retacrit
|
What is healthy male subjects?
Who was in the cross-over study which evaluated PK/PD similarity with Retacrit
|
What are Retacrit contraindications?
Uncontrolled hypertension, PRCA that begins after treatment with Retacrit or other erythropoietin protein drugs, serious allergic reactions to Retacrit or other epoetin alfa products.
|
|
What is single dose vials and singe dose prefilled syringes
Nyvestym is supplied
|
What is $11.03
Retacrit WAC price
|
What is mean absolute neutrophil count?
Primary PD endpoint to support biosimilarity to Neupogen
|
What are back pain, headache, pain in extremity, and injection site hemorrhage
Adverse Event Reported by at least 5% of subjects in the Nivestym treatment groups
|
|
What is 150 units/kg SC 3 times per week until completion of a chemotherapy course OR 40,000 units SC weekly until completion of chemotherapy course
The Retacrit dosing for adult patients on cancer chemotherapy
|
What is $350.40
Nivestym WAC price
|
What are patients with CKD on hemodialysis?
The Retacrit comparative clinical studies evaluated the efficacy and safety profile of SC and IV administration in this patient population
|
What is myelosuppressive chemotherapy?
ESAs should only be used in patients receiving this type of chemotherapy
|
|
What is 5mcg/kg/day
The Nyvestym dosing for patients with cancer receiving myelosuppressive chemotherapy or induction and/or consolidation chemotherapy for AML
|
What is $3.46 IU
Retacrit 340 B price
|
What is key inclusion criteria in Retacrit comparative clinical studies?
Patients with CKD and anemia, greater then or equal to 12 weeks stable dialysis, adequate iron stores and stable on Epogen treatment
|
What are thromboembolic events, cerebrovascular events, and myocardial infarction?
Adverse events of special interest in the Retacrit clinical trials.
|
|
What is discontinue?
After 8 weeks of therapy with Retacrit, if there is no response as measured by hemoglobin levels or if RBC transfusions are still required you should
|
What is 19 cents per micrograms
Nivestym 340 B price
|
What is the washout period in Nivestym crossover study?
At least 28 days between last dose in Period 1 and first dose in Period 2
|
What is 9 and O?
Number of subjects who tested Postive for ADA and Nab in the Nivestym group?
|
Support Us on Ko-fi